Share
I anticipate that there needs to be support on the trendline $1.38 a $1.40 otherwise there may be a reversal. The stock has been going up on anticipation of market penetration which has not materialised to date. No major wins since KP announcement and they have not even been hitting that out of the park. Makes you wonder if these guys can commercialise a technically excellent product.
the new CEO is of Medical persuasion - I wonder if they really wanted deployment capabilities. Time will tell. I hope that the product is so disruptive that the profession dictates that it must be had!
